Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 24, 2013

Novartis Cuts 300 Jobs, Names New CFO

  • Reporting its first-quarter financial results this week, Novartis announced a restructuring of its Lincoln, Nebraska manufacturing plant affecting 300 positions—40% of the total workforce at that site. The pharma giant also named Harry Kirsch its new CFO.

    Novartis plans to reduce staff at the Nebraska plant in phases during the next two years, in order to shift its focus on two product forms, the company said. “This will enable the site to focus on operational excellence, with minimal product complexity,” according to a Novartis statement.

    Kirsch, who was previously CFO Pharmaceuticals, has been promoted to Group CFO, the company said. He replaces Jon Symonds, who is being made advisor to the CEO through the end of the year.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »